Survival in chronic myelogenous leukemia: Influence of treatment and extent of disease at diagnosis Academic Article Article uri icon


MeSH Major

  • Cardiovascular Diseases
  • Genetic Variation
  • Indians, North American
  • Mannose-Binding Lectin


  • A retrospective study was conducted on the survival of 178 patients with chronic myelogenous leukemia from January 1948 through December 1967. Through analysis of survival time, comparison has been made between a group of 50 patients treated with chemotherapy alone vs. a group of 84 patients treated with radiation therapy to the spleen and chemotherapy. No difference could be found in these two major therapeutic groups (median survival 31 months for both). Further analysis has been made to determine whether survival could be correlated to the initial extent of disease. Initial hemoglobin value, WBC, platelet counts, absolute blast count, spleen size, and selected combination of these factors showed no significant correlation with survival. Acute blastic transformation occurred in 60% of 117 patients. Infection as a cause of death was less frequent in patients with progressive disease without acute blastic transformation, while renal failure due to hyperuricemia and thromboembolic phenomena occurred more often in this group as compared with patients dying in acute blastic phase. Copyright © 1973 American Cancer Society

publication date

  • January 1973



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197303)31:3<492::AID-CNCR2820310302>3.0.CO;2-4

PubMed ID

  • 4511907

Additional Document Info

start page

  • 492

end page

  • 501


  • 31


  • 3